[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351274-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351274-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ezh2-is-a-key-prognostic-marker-and-therapeutic-target-in-aggressive-and-proliferative-hepatoblastoma","EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma","","EZH2 is a histone methyltransferase and a key component of polycomb repressive complex 2 (PRC2), regulating genome remodeling and gene expression through both PRC2-dependent and independent mechanisms. Its role in hepatoblastoma remains insufficiently understood. Using published transcriptomic datasets and patient tissue samples, EZH2 mRNA and clinical features were correlated, while molecular, genetic, proteomic, and pharmacological approaches assessed EZH2 function. Results link EZH2 to poor prognosis markers and tumor proliferation, migration, survival, and cisplatin resistance, involving DUSP5 repression and DUSP9/HMGCR induction.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ezh2-is-a-key-prognostic-marker-and-therapeutic-target-in-aggressive-and-proliferative-hepatoblastoma/351274/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ezh2-is-a-key-prognostic-marker-and-therapeutic-target-in-aggressive-and-proliferative-hepatoblastoma/351274.png","ImageObject",300,407,{"name":42,"@type":43},"Mia  ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is EZH2, and why is it important in cancer biology?","Question",{"text":63,"@type":64},"EZH2 is a histone methyltransferase and a core component of PRC2. It regulates genome remodeling and gene expression through PRC2-dependent and independent mechanisms involving histone and non-histone targets.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study evaluate EZH2’s clinical and molecular relevance in hepatoblastoma?",{"text":68,"@type":64},"The work analyzed potential correlations between EZH2 mRNA and clinical parameters using computational and histological methods with seven transcriptomic datasets and patient tissue samples. It also used genetic gain- and loss-of-function tools, proteomics, immunohistochemistry, pharmacological drugs, 2D and spheroid assays, and multiple animal models.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic effects were observed when targeting EZH2?",{"text":72,"@type":64},"EZH2 inhibition with GSK126 showed synergy with statins in eradicating hepatoblastoma cells in vitro and blocking tumor development in mice. The data support EZH2 as a key driver of proliferative hepatoblastoma and suggest combined EZH2 inhibitor–statin benefit for treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351274,1790998016,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Khoubai etal. Molecular Cancer (2026) 25:77 Molecular Cancer  \n[https://doi.org/10.1186/s12943-025-02474-9](https://doi.org/10.1186/s12943-025-02474-9)  \nRESEARCH Open Access  \nEZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma  \nFatma Zohra Khoubai 1,2, Alexia Cal ovoulos 1,2,3†, Hélène Guillorit2†, Juan Carrillo-Reixach4,5†,  \nAlvaro del Rio-Alvarez4,5†, Pierre Klein 1,2, Marina Simon Coma2, Christophe Avignon6, Benoit Rousseau7, Lea Mora Charrot7, Sandrine Fedou 1,2,8, Jean-William Dupuy9, Laura Royo4, Montse Domingo-Sàbat4, Nadine Thézé 1,2, Géraldine Siegfried2,8, Abdel-Majid Khatib2,8, Stefano Cairo 10,11,12, Emilie Indersie 10, Buddhi Prakash Jain 13, Véronique Trézéguet 1,2, Etienne Gontier3, François Lamoureux 14, Catherine Guettier6, Charlotte Mussini6, Martin Hagedorn 1,2, Carolina Armengol4,5 and Christophe F. Grosset 1,2,15*  \nAbstract  \nBackground EZH2 is a histone methyltransferase and a key component of polycomb repressive complex 2 (PRC2) . It plays a critical role in genome remodeling, gene regulation and acts through PRC2-dependent and independent mechanisms, which comprise methylation of histone and non-histone substrates, and transcriptional activation through different transcriptional complexes. EZH2 is involved in many cancers, but its role in hepatoblastoma is poorly understood.  \nMethods Potential correlation between EZH2 mRNA expression and clinical parameters was analyzed by computational and histological approaches using seven published transcriptomic datasets and tissue samples from patients with hepatoblastoma. EZH2 molecular function was deciphered using molecular approaches, gain-and lossof-function genetic tools, proteomics, immunohistochemistry, pharmacological drugs, 2D cell-and spheroid-based assays, and four different animal models.  \nResults Our data show that EZH2 mRNA expression correlated with poor prognostic markers such as tumor proliferation, and patients’ death and shorter survival. EZH2 protein potentiated hepatoblastoma cell proliferation, migration, survival and cisplatin resistance through its histone methyltransferase activity by repressing DUSP5, and transcriptionally inducing DUSP9 and HMGCR. In vivo EZH2 sustained tumor cell proliferation, and tumor development and angiogenesis. The EZH2 inhibitor GSK126 synergized with HMG-CoA reductase inhibitor statins to eradicate  \n\n| †Alexia Calovoulos and Hélène Guillorit contributed equally to this work. |\n| --- |\n| †Juan Carrillo-Reixach and Alvaro del Rio-Alvarez contributed equally to this work. |\n\n*Correspondence: Christophe F. Grosset [christophe.grosset@inserm.fr](christophe.grosset@inserm.fr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nKhoubai et al. Molecular Cancer (2026) 25:77 Page 2 of 20  \nhepatoblastoma cells in vitro and block tumor development in mice. This combination was also very effective on various hepatoblastoma and non-hepatoblastoma tumor cell lines.  \nConclusion Collectively, our data showed that the protein EZH2 promotes hepatoblastoma dev","cbCaiofHJLGEHCzd","https://ap.wps.com/l/cbCaiofHJLGEHCzd","pdf",20806965,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is EZH2, and why is it important in cancer biology?\",\"answer\":\"EZH2 is a histone methyltransferase and a core component of PRC2. It regulates genome remodeling and gene expression through PRC2-dependent and independent mechanisms involving histone and non-histone targets.\"},{\"question\":\"How did the study evaluate EZH2’s clinical and molecular relevance in hepatoblastoma?\",\"answer\":\"The work analyzed potential correlations between EZH2 mRNA and clinical parameters using computational and histological methods with seven transcriptomic datasets and patient tissue samples. It also used genetic gain- and loss-of-function tools, proteomics, immunohistochemistry, pharmacological drugs, 2D and spheroid assays, and multiple animal models.\"},{\"question\":\"What therapeutic effects were observed when targeting EZH2?\",\"answer\":\"EZH2 inhibition with GSK126 showed synergy with statins in eradicating hepatoblastoma cells in vitro and blocking tumor development in mice. The data support EZH2 as a key driver of proliferative hepatoblastoma and suggest combined EZH2 inhibitor–statin benefit for treatment.\"}]","EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma | PDF",1790093304,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e2d580e71bc7905bc9b17323f3ca93d.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44ac919ad2c5fedd7e2f55ff6338930a.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55a9debd8b8ad6cf7de933d8d52445b3.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd2ac912a1f22cc2688e9ceb6c740c7c.webp",980,1306]